All Eyes on Licensing Partners and Shape of the Deal; Maintaining FVE for Acrux
No-moat Acrux reported full-year results in line with expectations both at the top and bottom lines marking the end of a difficult 12 months. Reported full-year loss of AUD 9 million, excluding impairments, on group revenue of AUD 2.7 million compared with our forecast loss of AUD 9 million on group revenue of AUD 2.6 million. Nonetheless, Acrux ended fiscal 2018 on a high note with AUD 28.5 million in cash on hand and 13 products in the generic pipeline. Given the recent announcement of its Abb...Acrux is a pharmaceutical company engaged in the development and commercialization of specialty and generic transdermal and topical pharmaceuticals for global markets. Co.'s topical or transdermal pharmaceutical product portfolio can be segregated into two streams - generic pharmaceutical products and specialty pharmaceutical products.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.